Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Catheter Precision ( (VTAK) ) has provided an announcement.
On July 25, 2025, Catheter Precision held its Annual Meeting of Stockholders, where six proposals were considered and approved, including the election of a director and several stock issuance proposals. A significant decision was the approval of a reverse stock split at a ratio of 1-for-19, effective August 15, 2025, aimed at maintaining the company’s compliance with NYSE American’s listing requirements. This reverse stock split will reduce the number of outstanding shares from approximately 23.3 million to 1.2 million, ensuring the company’s continued listing on its current exchange without altering stockholders’ equity percentage.
Spark’s Take on VTAK Stock
According to Spark, TipRanks’ AI Analyst, VTAK is a Neutral.
Catheter Precision’s overall stock score is primarily hindered by its poor financial performance and valuation, reflecting significant operational and profitability challenges. Technical analysis confirms bearish momentum, while corporate events offer a blend of opportunities and risks. The company’s ability to improve its financial health and capitalize on product sales growth will be critical in enhancing its stock performance.
To see Spark’s full report on VTAK stock, click here.
More about Catheter Precision
Catheter Precision, Inc. operates in the medical device industry, focusing on developing innovative solutions for cardiac electrophysiology. The company is known for its products that aid in the diagnosis and treatment of heart rhythm disorders.
Average Trading Volume: 14,760,690
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.76M
Learn more about VTAK stock on TipRanks’ Stock Analysis page.